John Libbey Eurotext

European Journal of Dermatology


Detection of IgG antibodies to BP180 NC16a and C-terminal domains and LAD-1 in nivolumab-associated bullous pemphigoid Volume 29, numéro 5, September-October 2019


  • Figure 1
1 Department of Dermatology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
2 Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
3 Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan

Nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, is used for the treatment of melanoma, lung cancer, and renal cancer [1]. Cutaneous lesions, including, non-specific exanthemas, lichenoid reactions, and vitiligo, are frequently observed as immune-related adverse events [2]. We herein report a case of bullous pemphigoid (BP) with IgG antibodies to BP180 NC16a and C-terminal domains and LAD-1, which might be related to nivolumab treatment.A 71-year-old Japanese man visited our hospital [...]